Middle Molecular Uremic Toxin and Blood Purification Therapy.

MCO-membrane blood purification hemodiafiltration middle molecules α1-microglobulin

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 21 12 2023
revised: 18 01 2024
accepted: 20 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5-58 kDa, and new classifications of "small-middle 0.5-15 kDa," "medium-middle 15-25 kDa," and "large-middle 25-58 kDa" were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.

Identifiants

pubmed: 38337341
pii: jcm13030647
doi: 10.3390/jcm13030647
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Hideki Kawanishi (H)

Tsuchiya General Hospital, 3-30 Nakajima-cho Naka-ku, Hiroshima 730-8655, Japan.

Classifications MeSH